6-K
Medicenna Therapeutics Corp. (MDNAF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2024
Commission File Number: 001-39458
Medicenna Therapeutics Corp.
(Translation of registrant’s name intoEnglish)
2 Bloor St. W. 7^th^ Floor
Toronto, Ontario M4W 3E2
Canada
(Address ofprincipal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| x Form 20-F | ¨ Form 40-F |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Medicenna Therapeutics Corp. | |||
|---|---|---|---|
| (Registrant) | |||
| Date: January 5, 2024 | By: | /s/ Fahar Merchant | |
| Name: | Fahar Merchant, PhD | ||
| Title: | Chief Executive Officer |
Form 6-K Exhibit Index
| ExhibitNumber | Document Description |
|---|---|
| 99.1 | Notice of Change of Auditor |
| 99.2 | Letter from Predecessor Auditor |
Exhibit 99.1
MEDICENNA THERAPEUTICS CORP.
(the “Corporation”)
NOTICE OF CHANGE OF AUDITOR
| TO: | Alberta<br>Securities Commission |
|---|---|
| British Columbia Securities Commission | |
| Ontario Securities<br>Commission | |
| AND TO: | PricewaterhouseCoopers LLP (“PwC”) |
| --- | --- |
Pursuant to National Instrument 51-102 – ContinuousDisclosure Obligations (“NI 51-102”), the Corporation hereby gives notice as follows:
1. On December 20, 2023, PwC resigned as auditor of the Corporation.
2. There were no reservations or modified opinions contained in PwC’s report on the financial statements of the Corporation or its predecessor for the financial years ended March 31, 2023 or March 31, 2022.
3. In the opinion of the board of directors of the Corporation (the “Board”), there have been no “reportable events” as such term is defined in NI 51-102, between the Corporation and PwC.
4. Following the resignation of PwC, the contents and filing of this notice have been recommended by the audit committee of the Corporation and approved by the Board.
Dated this 20^th^ day of December, 2023.
MEDICENNA THERAPEUTICS CORP.
| Per: | (s) Fahar Merchant | |
|---|---|---|
| Name: | Fahar Merchant | |
| Title: | President and Chief Executive Officer |
Exhibit 99.2
December 20, 2023
| To: | Alberta Securities Commission |
|---|---|
| British Columbia Securities Commission | |
| Ontario Securities<br>Commission |
We have read the statements made by Medicenna Therapeutics Corp. in the attached copy of change of auditor notice dated December 20, 2023, which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102.
We agree with the statements in the change of auditor notice dated December 20, 2023.
Yours very truly,
Chartered Professional Accountants
PricewaterhouseCoopers LLP
PwC Centre, 354 Davis Road, Suite 600, Oakville, Ontario, Canada L6J 0C5
T: +1 905 815 6300, F: +1 905 815 6499, [email protected], www.pwc.com/ca
“PwC” refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.